Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Amantadine appears to be a specific substrate for acetylation by spermidine/spermine
N1-acetyltransferase (SSAT). SSAT activity in cancer cells is higher by several-fold compared
to normal cells. Amantadine can be used to determine SSAT cellular activity, and may indicate
the presence of cancer.
This study will provide additional information in conjunction with data from a previous study
which include cancer patients and normal health age matched controls to determine whether
urinary excretion of acetylamantadine is predictive for the presence of cancer, and if so
whether excretion of this metabolite is associated with any particular site of the tumor.
Based on the results of the first study additional data in normal healthy volunteers is
required.
The data from both studies will be analyzed to account for subject gender, stage of disease
at time of testing, concurrent diseases, alcohol and tobacco use and occupational
characteristics. This is an important first step in validating a cancer detection method that
can be implemented economically for screening of large numbers of people at sites remote from
limited and expensive diagnostic instrumentation. Thus there is a possibility that this
design can be prognosis biomarker as well as a positive/negative indicator.
Phase:
N/A
Details
Lead Sponsor:
University of Manitoba
Collaborators:
St. Boniface General Hospital Research Centre St. Boniface Hospital